PIPELINE

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Scientific illustration of a pancreas with a pancreatic ductal adenocarcinoma

What is Pancreatic Ductal Adenocarcinoma (PDAC)?

PDAC is the most common tumor arising in the pancreas, accounting for about 85-90% of cases.1 There are usually no symptoms in the early stages2 and by the time of diagnosis, pancreatic cancer has often grown beyond the limits of surgical therapy and/or spread to other parts of the body, including nearby lymph nodes, liver, peritoneal cavity, or lungs.3,4 

PDAC  typically has a very poor prognosis with a 5-year relative survival rate of 9% for all stages and 3% for advanced disease.5

The TriSalus™ Approach to Studying a Treatment for Locally Advanced PDAC

Unlike the liver, the pancreas does not have an easily accessible arterial system feeding it, making regional intravascular delivery challenging using the traditional antegrade approach. Retrograde venous delivery of investigational nelitolimod (also known as SD-101), which involves placing our FDA cleared device into the veins draining the pancreas and using Pressure-Enabled Drug Delivery™ (PEDD™) to administer the drug, provides a potentially more feasible and reliable strategy for targeted delivery to pancreatic tumors. Importantly, the nelitolimod treatment is being given in combination with a systemic or intravenous immunotherapy to potentially enable treatment of tumors outside of the pancreas, in addition to tumors within the pancreas.

TriSalus’ proprietary Pancreatic Retrograde Venous Infusion (PRVI™) delivery using our PEDD method to administer drug into the venous system allows for the study of investigational nelitolimod delivered directly into locally advanced tumors within the pancreas.

Nelitolimod is in clinical development and has not been approved in the US or globally.

Platform

Immunomodulatory drugs have the potential to reactivate the immune system.

TriSalus' Pipeline

We are studying the combination of nelitolimod with PEDD to enable immunotherapies in the liver and pancreas. Our clinical research is focused on bringing this potentially transformative treatment platform to patients.

PIPELINE

CITATIONS

1. Kim SS, et al. J Belg Soc Radiol. 2018; 102(1):71.
2. National Cancer Institute. Published Online, 2020.
3. Ryan DP, et al. N Engl J Med 2014; 371:1039-1049.
4. Wolfgang CL, et al. CA Cancer J Clin. 2013;63(5):318-348.
5. American Cancer Society. Published online, 2020

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL